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The effect of light on drugs has, until recently
been considered relatively unimportant, even
though the storage instruction Protect from Light
is being prescribed by the pharmacopoeias for
an increasing number of drugs and excipients.·
Despite the fact that there has been much
publicity over the years about the incidence of
skin cancers especially in countries such as
Australia, there has been limited awareness raised
about the combined effect of light and drugs on
the human skin. 2 Although therapeutic inactivity
is not a likely outcome, it is important to consider
that even minor photodegradants may result in
light-induced side-effects3 e.g. photosensitivity
reactions in patients.
Photosensitivity may be defined as an adverse reaction to
light, which may be phototoxic orphotoallergic in nature. 4
Knowledge of light and drugs allows the
pharmacist to offer advice on:
Handling, packaging, labeling and distribution of
drug products
Adverse effects (photosensitivity reactions)
Therapeutic aspects and new drug delivery systems.
DrugS may be exposed to a variety of lightconditions, including direct sunlight, filtered(window) sunlight and various artificial light
sources during manufacture, storage, distribution and
administration to the patient Although the ultraviolet
(UV) component of sunlight is considered the most
problematic, exposure to fluorescent lighting for
prolonged periods of time needs to be taken into
consideration in terms of the spectral distribution of
these light sources, which extends from 300nm to
3000nm. UV-C (200-280nm), UV-B (280-320nm)
and UV-A (320-400nm) comprise the three regions of
the UV-spectrum. Although eliminated from the earth's
surface by absorption by molecular oxygen and ozone,
UV-C, which may cause adverse effects, is present in
artificial light sources such as germicidal lamps and
welding arcs. Although the UV-A reaches the earth's
surface to a greater extent than that of UV-B, it is the
UV-B which causes sunburn and skin cancer. While
sunlight and fluorescent light sources have a high output
Learning objectives
After reading this article you should:
Differentiate between photoallergic and
phototoxic reactions in patients.
Recognise drugs with the potential to degrade
on exposure to light during handling, storage
and distribution.
Recognise drugs with the potential to cause
photosensitivity reactions in patients.
• Recommend management strategies to
ensure the stability of drug products and to
prevent and treat photosensitivity reactions in
patients.
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in the visible region of the spectrum (400-800 nm), the
significant output in the UV-region must be noted for
the fluorescent light sources. Most drugs absorb UV-C,
while UV-B is responsible for the photoreactivity of
drugs in the presence of sunlight and UV-A in addition
to being absorbed by DNA, may cause photosensitisation
reactions. In order to cause a reaction, the UV radiation
must penetrate, whether it is the drug in the formulation
or in the patient. The former is dependant on the
transparency of the packaging. In the patient, although
UV radiation shorter than 320nm penetrates the
stratum corneum of the Caucasian skin, it must reach
the absorbing drug molecule in the peripheral blood
capillaries in order to illicit a photochemical response.s
Requirements for a drug to be
considered as having a potential to cause
photosensitivity reactions in a patient:6,7
• The drug and/or metabolitelphotodegradant must be
present in the tissues at the body surface such as the skin,
eyes and/or hair.
The drug must be in a sufficiently high accumulative
dose.
The drug must degrade on exposure to light forming
degradants and/or metabolites which are susceptible to
photodegradation.
The drug must contain chemical functions which are
known to be photoreactive.
Studies into the photoreactivity of drugs provide
us with important information about the potential for
photosensitivity effects in patients, instructions for
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Table 1: Chemical functions and
photoreactivity.8
I I
Description Chemical function III
I
I
-Carbonyl group
-c=o I
I
-Nitroaromatic group Ar-N02 !I
-N-oxide group -N~O I
I
I
I
-Double bond
-C=C- I
I-Aryl chloride group Ar-CI
-C-H bond at a benzylic
position or a to amine-N -N-CH,-
-Sulfides, phenols -SH, -OH
packaging and storage and also alert us to the possibiliry
of in-use photoinstability. In-use photostability must be
considered when pharmacists repackage drugs and/or
patients remove drugs from the original/manufacturer's
container.
1. Photoreactivity of drugs
It is possible to predict the photoreactivity of drugs
based on certain molecular features, which are likely to
make the drug photolabile. It should also be noted that
a drug which displays photoreactivity in vitro does not
necessarily give rise to adverse photosensitivity effects in
patients.
Several chemical functions are capable of introducing
photoreactivity into drugs (Table 1).
Case study
A patient supplied with a chloroquine syrup in a
rural and remote location returns to the clinic a
few days later with a query, Due to the lack of
availability of a liquid dosage form at the clinic, the
syrup has been extemporaneously compounded
using chloroquine tablets, a suspending agent
(sodium carboxymethylcellulose), syrup and
compound hydroxybenzoate solution APF in
a clear glass medicine bottle. The patient is
concerned that the syrup has undergone a color
change from white to yellow.
Although these chemical functions are present in a
large variety of drugs, the photoinstability of these drugs
is dependent on absorption of ambient light at >330nm
and is also dependent on the dosage form, which may
be a concentrated solution or in the solid-state, and
thus photoreaction may be too slow to be of practical
importance, as opposed to dilute solutions where
degradation may be rapid. Although drugs degrade to
different extents on separate exposure to heat, moisture,
air (including oxidation) and light, combinations
of these stresses can cause complex behaviour. The
pharmacist needs to be aware that photodegradation
can be accelerated by heat and thus storage instructions
to patients in tropical climates are important. In drug
formulations, the presence of excipients adds further
complications because the excipients may increase, have
no effect on, or decrease the inherent stabilities of the drug.'
However, even a drug in the solid-state may
undergo a color change (reactions take place only in a
thin surface-layer) on exposure to light and different
polymorphic forms of a drug may degrade at different
rates. 10 This change in color might not relate to chemical
degradation of the drug; however the ability to effect
changes in the physical stability such as tablet hardness,
friability, disintegration and dissolution needs to be
considered due to the potential changes in bioavailability
and thus therapeutic efficacy. However preparation
of liquid dosage forms may also result in a change in
the polymorphic form of the drug substance. Drug
products intended for use in areas such as tropical north
Queensland are exposed to severe conditions of light,
heat and moisture and are required to maintain stability
e.g. the antimalarial drug, chloroquine which although
most frequently used as tablets is also formulated as an
injection, solutions and syrups" and is susceptible to
photodegradation.
Management strategies for patients and
or other health professionals about drugs
susceptible to photodegradation should
include:
Storage instructions in respect ofheat, and exposure to
air and light.
Instructions re removal of the drug product from its
original container or removal of an outer cardboard
sleeve.
The pharmacist also has a role to play in monitoring
the distribution channel and storage of drugs by health
professionals in rural and remote locations.
2. Photosensitivity effects of drugs
Phototoxicity and photoallergy are the two major
types of photosensitisation. Phototoxicity occurs more
frequently than photoallergy and does not involve an
immunological mechanism. Phototoxic reactions, which
resemble severe sunburn and may even blister, are dose
dependent for both drugs and sunlight. These reactions
occur immediately after, or within a few hours of taking
the drug and simultaneous exposure to radiation of the
appropriate wavelength (usually from 300-400nm) and
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Systemic drugs - class Drugs
Table 2: Drugs implicated in photosensitivity reactions 12.13
I T.,k.1 ,,,,,,,,",.n,
Antihistamines, antiseptics, coal tar derivatives, sunscreens, retinoid topicals
will subside if the drug is withdrawn and/
or if possible the patient avoids excessive
exposure to sunlight. Phototoxicity may
cause damage to cells by modification of
certain targets such as DNA, lipids and/or
amino acids and proteins. Photoallergy is
immune-mediated, whereby the drug, on
exposure to radiation, combines with a
protein or perhaps a biomacromolecule in
the skin to form an antigen, leading to an
immune response. Photoallergic reactions
are not dose dependent and require several
exposures and an induction period. The
low incidence of photoallergic reactions
may be attributed to the body's immune
response mechanisms. Photoallergy has
a different histology compared to that of
phototoxicity, manifesting as eczematous,
lichenoid, urticarial, bulbous or purpuric
rashes. 12
NSAIDs
Diuretic drugs
Antipsychotic drugs
Antibacterial drugs
Antimalarial drugs
Antidepressant drugs
Cardiovascular drugs
Hypoglycaemic drugs
Anticonvulsant drugs
Antihistamine drugs
Naproxen, ketoprofen, piroxicam, diclofenac
HydrochlorothillZide, frusemide, chlorothillZide
Chlorpromazine, prochlorperazine. chlorprothixene
Demeclocycline, nalidixic acid, su/phamethoxazole,
ciprof/oxacin, oxytetracycline, doxycycline
Chloroquine, quinine, mef/oquine
Amitryptyline, trimipramine, nortriptyline, doxepin
Amiodarone, nifedipine, captopri/, enl1lapril
Glibenclamide, tolbutamide, chlorpropamide
Carbamazepine, lamotragine, phenobarbital
Cyproheptidine, diphenhydramine, triprolidine
Table 2, although not comprehensive,
represents the topical preparations, major
systemic drug classes and those drugs
within these classes most frequently
implicated in photosensitivity reactions.
Although these drugs represent a wide
variety of chemical structures, there are
certain general characteristics which these
drugs have in common, including: 13
Low molecular weight (200-500 Daltons)
Planar, tricylic or polycyclic structures
Heteroatoms for resonance stabilisation
Absorption ofWand / or visible radiation.
Although it may be possible to some
extent to predict the photodecomposition of
drugs related to their molecular structure and
alert the pharmacist to potential problems in
packaging and storage and adverse effects
in patients, there has been no reported
relationship between chemical structure and
photosensitivity effects in patients.
Topical agents such as antihistamines,
antiseptics, coal tar derivatives, sunscreens
and more recently retinoid creams
have been implicated in photosensitivity
reactions. Phototoxicity has been reported
on application of coal tar preparations,14.1l
while photo-contact dermatitis may be
attributed to some sunscreens. Since
both the UV-A and UV-B ranges of the
spectrum need to be covered, a broad
spectrum sunscreen is recommended to
include a cinnamate ester (UV-B) and
a benzophenone such as 4-methoxy-2-
hydroxybenzophenone (UV-A). Both of
these compounds absorb sunlight energy,
whereas titanium dioxide and zinc oxide
provide barrier protection. Titanium
dioxide l6 is reported to block UV-A and
UV-B (to 340 nm), whereas zinc oxide
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Figure 2: Drugs implicated in photosensitivity reactions - amiodarone
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In the case of the nonsteriodal anti-
inflammatory drugs (NSAIDs - Figure 3),
it is often described as ironic that drugs
designed to prevent inflammation result
in inflammation due to photosensitivity
Case study
Mr HM comes into the pharmacy to
ask about sun protection. He is a
keen surfer and is currently spending
a lot of time on the beach in Caims.
He is concemed that areas of his
skin not covered by his wetsuit are
more prone than usual to sunbum
even blistering. When asked
Mr HM responds that he is not using
a broad spectrum sunblock and that
he has been taking naproxen for
the last week, recommended to him
because he has been having some
trouble with his knee.
Figure 1: Drugs implicated in photosensitivity reactions -
chlorine substituents
Amiodarone
being chlordiazepoxide, which although
implicated in photosensitivity reactions
does not undergo photodehalogenation.
Because the chlorine-containing drugs are
frequently implicated in photosensitivity
reactions, it must be said that the
liberation of free radicals plays a major
role in these adverse effects experienced
by patients. -
Amiodarone photosensitivity in
patients has been reponed to be dose-
reIated20· 21 with the slate blue22 discoloration
on sun-exposed areas attributed to the
deposition of lipofuscin, a product of
lipid peroxidation.23 The photochemical
mechanism may be explained by
photodehalogenation (removal of the
iodine - Figure 2) with the aryl radicals
formed, extracting hydrogen from
linoleic acid and leading to peroxy radical
formation.
because of its larger particle size covers
both the UV and visible ranges. More
recently Pinnell, et al'?·" have reported on
the properties of microfine zinc oxide both
in terms of its superior sun protection
when mixed with octyl methoxycinnamate
(and photostability) and when compared
to that of microfine titanium dioxide.
It is important that sunscreens do 'not
undergo photodecomposition as even
stable photoproducts formed in very low
concentrations may produce significant
toxic effects during actual sunscreen
usage. Because of this concern the use of
p-aminobenzoic acid (PABA) has declined
significantly as reportS on the production
of reactive intermediates on exposure
to light, with subsequent reaction with
oxygen forming oxidants is known to
produce toxic effects.
Photosensitising mechanisms may be
photophysical and lor photochemical in
nature. For photosensitisation to occur, it
is a requirement that there is an overlap
between the absorption spectrum of
the drug and the incident light energy
with wavelengths of <300nm implicated
to a greater extent in these reactions.
Nonsteroidal-antiinflammatory, di uretic
and antibacterial drugs are considered
significant as photosensitising drugs and
a photochemical basis for this reactivity
has been determined. In addition, the
reactivity of many photosensitising drugs
across the pharmacological classes has
been attributed to the presence of an
aromatic chlorine (Ar-Cl) substituent
as illustrated in figure 1 for frusemide,
hydrochlorothiazide, chlorpromazine and
chloroquine. In these reactions, this bond
is dissociated (photodehalogenation) with
the liberation of Hel and a mixture of
reduction and substitution products. For
chlorpromazine, it has been reported that,
in addition to the degradants formed
on exposure to light, a decrease in pH
is observed" with the liberation of HCI
reported to contribute to a decrease in
pH. These findings explain the sensitivity,
inflammation or dermatitis that usually
precedes the deposition of melanin in the
skin of patients treated with large doses
of this drug. It must be noted that not
all chloroaromatic drugs undergo this
type of reaction with a notable exception
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Figure 3: Drugs implicated in photosensitivity reactions - NSAIDs there have been some photosensitivity
reports on use of celecoxib, etodolac and
rofecoxib. (etodolac and rofecoxib are not
available in Australia)
The most photoactive in this class
of drugs are the 2-arylpropionic acid
derivatives such as naproxen due
to removal of the carboxyl group
(-COOH photodecarboxylation)
occurring. Although ibuprofen has been
reported co be a photosensitiser, its
absorption spectrum is weak. However
the availabiliry of both ibuprofen and
naproxen without a prescription has led
co widespread use and presents a role for
the pharmacist in counselling patients
about potential photosensitiviry effects on
excessive exposure to sunlight. In addition
to being able to produce free radicals, the
2-arylpropionic acid derivatives can
produce significant yields of singlet
oxygen (the oxygen molecule in an
excited singlet state - the ground state
of oxygen is the triplet state5). Singlet
oxygen and free radicals thus generated
may phocooxidise biological substrates
such as membranes, lipids and proteins
disrupting cells and causing oxidative
stress and adverse reactions such as
photosensitiviry effects." Singlet oxygen
yields for naproxen are significant and this
together with an efficient decarboxylation
process should alert the pharmacist co
a need for patient counselling. Some
photosensitiviry effects have been reponed
in patients taking piroxicam.25•26 However,
there is some controversy as to whether
with photosensitiviry responses. Although
the issue of gastric irritation has been
addressed in the newer drugs in this class,
PiroxicamDiclofenac
DemeclocycUne
reactions and in fact while gastric
IrrItation is often the major side effect
of this drug class, many patients present
Figure 4: Drugs implicated in photosensitivity reactions - antibacterials,
I
PHarmacist Volume 25 I Number 2 I February 2006
CPD&PI
~? ..........,...,~,z. Soc:lety of Australia
Submit your answers online at www.psa.org.au and receive automatic feedback
---------------------------------_/
Management strategies for
prevention and treatment of
photosensitivity reactions in
patients should include:'3
Beverley Glass is Professor of Pharmacy at
the James Cook University. She has been
researching in the area of the photostability of
drug molecules for 15 years and recently has
focused on in-use drug stability and is interested
in the clinical applications of light and drugs,
especially photosensitivity effects and ocular
phototoxicity in patients.
concentration needs to be taken into consideration in
otosensitMty reactions and this involves the dosage of
rug concerned.
this may be attributed to a metabolite of
piroxicam, due to the fact that there is
no correlation between the in vivo and
in vitro findings or the photo-oxidation
process. 27. 28 In the case of diclofenac, after
photodehalogenation (removal of both
chlorine atoms) takes place, the carboxyl
group remains intact which allows the
photoproduct to be readily excreted.
Drug concentration needs to be taken
into consideration in all photosensitivity
reactions and this involves the dosage of
the drug concerned - the higher the dose
the higher the circulation concenttation of
the drug and the greater the potential for
a photosensitivity reaction to occur. This
needs to be taken into consideration when
comparing the ability of naproxen and
diclofenac to cause photosensitivity effects
in patients.
In the antibacterial class of drugs
(Figure 4), the tetracyclines especially
demeclocyline (effective generator of
singlet oxygen and free radicals - now
rarely used) and oxytetracycline have been
prominent in reports on photosensitivity
reactions due to their extensive absorption
spectrum in the UV-A region. Although
these two have been largely replaced by
doxycycline and minocycline, which have
resulted in fewer phototoxic effects, some
sunlight-induced pigmentation may still
occur on exposed skin. 29 Again the dosage
regimen of these drugs needs to be taken
into consideration, not only in terms of
drug concentration but also the duration
of the regimen especially when doxycycline
is used in malaria prophylaxis. For the
fluoroquinolones, photodehalogenation,
in this case cleavage of the C-F bond
may produce radicals which can cause
similar cell-mediated damage to that
of their chlorinated counterparts. JO
When cotrimoxazole was found to cause
photosensitivity effects in patients, it was
proposed that sulphalllethoxazole was
causing these reactions due to cleavage of
the N-O bond.
•
•
•
Use ofa broad spectrum sunblock.
Avoidexcessiveexposure to sunlight, andwear
suitableprotective clothing and eyewear.
Treat sunburn-like reactions with emollients/
oatmeal baths, soothing creams andgels.
Treat inflammation with:
Topical corticosteroids22 (such as
hydrocortisone) may be recommended
up to three times per day, however
issues such as the area concerned and
the status of the skin are important
considerations.
Antihistamines may be recommended
(if urticaria is present) such as
cetirizine 10mg orally, daily and ifthe
urticaria persists and is non-responsive,
the addition ofa second antihistamine
such as promethazine 25mg orally, at
night may be considered.
Withdrawal ofthe photosensitising drug
ifnecessary.
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Tra9t sunbum-like ra9ctions with emollients/oatmeal baths,
soothing crooms and gels.
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